Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Friday, November 2, 2018

uBiome: World's largest Human Microbiome Dataset

Click on icon
to see full article




uBiome - The Largest
Human Microbiome Dataset



Did you know that uBiome has the largest human microbiome dataset in the world? We're sharing our story of how we built this dataset, what we've learned from it, and what this means for the future of microbiome science.

Initially, uBiome collected 2,500 samples in a crowdfunding campaign. Now, six years later, uBiome has over 250,000 samples from all over the world, with over 1 million projected in 2019.
Click below to read more about what uBiome has learned so far:
As noted in previous posts, MEBO Research is most grateful to uBiome for the research grant they have provided us, which includes providing us with 3 sample collection Explorer Gut kits for over 100 participants around the world and the sequencing of the microbiome of each sample for the Clinical Trial, "Microbial Basis of Systemic Malodor and PATM Conditions (PATM)" registered with ClinicalTrials.gov. To see all posts regarding this research study, click here.

In addition to sequencing the samples of the MEBO participants, they are provided with a comparison of each sample results to those of the 250,000 samples in the uBiome dataset. These results are then given to the Principal Investigator of this study, Dr. Irene Gabashvili, PhD., MEBO Scientific Director, to further analyze these results in relations to odor and PATM conditions. Dr. Gabashvili describes the details of the study:

Human odorprints, mostly owing to the microbiome, have proven their value as biomarkers of health and environmental exposures. In recent years, microbial networks responsible for localized malodors such as halitosis or axillary odor have been mapped by using next generation sequencing approaches. Intestinal microbes responsible for psychologically debilitating systemic malodor (whole-body and extraoral halitosis), however, remain to be identified. Even a relatively straightforward disorder of choline metabolism trimethylaminuria (TMAU) is thought to exhibit complex host-gene microbiome interactions and has not been sufficiently studied.

Proposed controlled pilot study aims to explore the dynamics of microbial communities in remission and flare-up periods. Better knowledge of the important aspects of disease fluctuation should enhance patient care and, combined with our prior data, will help to develop new therapies and treatments.
https://clinicaltrials.gov/ct2/show/NCT03582826

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

2 comments:

Anonymous said...

I THINK THAT ITS SO SAD THAT THIS IS ALL THEY HAVE COME UP WITH SINCE 1970, WHICH IS WHEN ONE OF THE FIRST CASES OF TMAU HAS BEEN BROUGHT UP, I MEAN, THESE SCIENTIEST MUST KNOW SOMETHING BY NOW ABOUT HOW TO STOP TMAU ODORS, COME ON PEOPLE, A PERSON WITH TMAU IS GOING TO BE THE ONE TO FIGURE THIS OUT BEFORE THE SCIENTIST DO,I HEAR OF PEOPLE WANTING TO KILL THEMSELVES OVER THIS CONDITION BECAUSE OF THE RIDICULE THATS PLACED UPON THEM, SO MUCH MORE NEEDS TO BE DONE, PEOPLE ARE CONTEMPLATING SUICIDE FOR GOD SAKE. PROCTOR AND GAMBLE HAS A PILL WAITING FOR 2020 TO PUT ON THE MARKET, BUT WHY WAIT UNTIL THEN, PEOPLE ARE DYING. I JUST DON'T GET IT AT ALL.

Nov 4, 2018, 10:57:00 AM
Anonymous said...

GRACIAS MARIA POR SU FUNDACION

Nov 8, 2018, 7:11:00 PM
Post a Comment